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Abstract.  We previously found that the CD44 glyco- 
protein on some lymphocytes can mediate adhesion to 
hyaluronate (HA) bearing cells. However, many ques- 
tions remain about the molecular heterogeneity of 
CD44 and mechanisms which control its recognition 
of this ligand.  In vitro mutagenesis and DNA sequenc- 
ing have now been used to investigate the importance 
of the membrane proximal region of murine CD44 for 
recognition of soluble or cell surface HA. CD44 with 
an 83 amino acid deletion in this region mediated bind- 
ing to soluble ligand and the apparent avidity increased 
markedly in the presence of a particular antibody to 
CD44,  IRAWB14.  The shortened CD44 was however 
inefficient in mediating adhesion of transfected cells to 
HA immobilized on cell surfaces. Four new murine 
isoforms of CD44 were isolated from a carcinoma line 
by use of the polymerase chain reaction.  Only two of 
them correspond to ones recently discovered in rat 
and human cells. The longest variant nearly doubled 
the length of the extracellular portion of the molecule 
and introduced an additional 20 potential sites for 
glycosylation. When expressed on T lymphoma cells, 
all four of the new murine CD44 isoforms were capa- 
ble of mediating adhesion to HA bearing cells. This 
result contrasts with a report that a related human 
CD44 isoform lacks this ability when expressed on B 
lineage lymphoma cells. The new routine isoforms 
also conferred the ability to recognize soluble HA and 
were very responsive to the IRAWB14 antibody. A 
brief survey of normal murine cell lines and tissues 
revealed that the hemopoietic isoform was the most 
abundant species. These findings indicate that the 
NH2-terminal portion of CD44 is sufficient for HA 
recognition and that this function is not necessarily 
abrogated by variations which occur in the membrane 
proximal domain.  They add to the known molecular 
diversity of CD44 and provide another experimental 
model in which isoform specific functions can be 
investigated. 
C 
D44 has been implicated  in a variety of functions, 
which include hemopoiesis, tumor metastasis,  and 
cell homing, as well as the activation of lymphocytes 
and monocytes (13-15, 30, 44). Some of these processes may 
depend on the ability  of CD44 to recognize  HA.t For ex- 
ample,  CD44 bearing lymphoid cells can adhere to stromal 
cells and to certain endothelial  cells by recognition  of sur- 
face HA (27, 31). However, while virtually all normal blood 
cells express CD44, most do not have measurable affinity for 
HA (19, 27-29). The situation may be comparable to certain 
other cell adhesion  molecules (CAM's)  whose recognition 
function requires activation of the cells which express them 
(35). Indeed, activated B lymphocytes taken from mice with 
graft versus host disease or stimulated  with IL-5 become 
adhesive  for HA coated surfaces and some lymphomas are 
induced to recognize  HA via CD44 after exposure to phor- 
bol ester (19, 33, 34).  While the molecular basis for reg- 
ulation  of ligand recognition  by this molecule is unknown, 
possible mechanisms include structural  diversity, conforma- 
1. Abbreviations  used in this paper:  HA, hyaluranate; PCR, polymerase 
chain reaction. 
tional changes, focal clustering on the cell surface and inter- 
action with other cell surface molecules. There is also recent 
evidence that association with cytoskeletal proteins may be 
cell type or activation dependent and possibly regulated  by 
phosphorylation of intracellular  serine residues (2, 4, 21, 22, 
26). We previously found that the cytoplasmic domain is im- 
portant for the adhesive function and that antibodies to par- 
ticular epitopes on CD44 may dramatically  increase ligand 
binding  (27). 
It has been known for some time that extensive posttransla- 
tional modifications of CD44, which involve O- and N-linked 
glycosylation,  and in some cases, addition of chondroitin  or 
heparan sulfates,  account for some of the observed hetero- 
geneity in molecules (3, 11, 23, 24, 36). More recently, mul- 
tiple isoforms of rat and human CD44 have been described 
which may result from alternative exon utilization (3, 8, 14, 
17, 42). This additional  diversity has been associated with 
differences in growth rates in vivo and metastasis of tumors, 
as well as differences in HA recognition  (14, 42, 43). These 
naturally  occurring isoforms all display variations  within a 
membrane proximal  region of CD44. 
We have investigated the importance of this domain for 
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murine isoforms which differ in this region. The function of 
mutated and naturally  occurring variants of CIM4 were as- 
sessed after transfection  into CD44 negative T lymphoma 
cells.  We conclude that the NH~-terminal  167  residues of 
CD44 are sufficient for recognition of HA when expressed 
on an appropriate cell type. Furthermore, this function is not 
necessarily dependent on sequence diversity involving the 
membrane proximal domain. Marked  augmentation of HA 
binding by an enhancing monoclonal antibody was observed 
with all CD44 isoforms and variants. 
Materials and Methods 
Cells, Cell Cultures, and Antibodies 
The murine T lympboma AKR1 (18) was maintained in DME with 10% 
FCS and antibodies.  The BM-2 B cell hybridoma, the 70Z/3 pre-B lym- 
phoma, the W231 B lymphoma (30) and BMS-2 stromal  cells (37) ware 
cultured in RPMI 1640 supplemented with 10% FCS,  50/~M 2-ME and 
antibiotics. The murine squamous cell carcinoma KLN205, Lewis lung car- 
cinema LL/2 and NIH 313 cells were obtained through the American Type 
Culture Collection (ATCC, Rockville,  MD) and maintained in MEM with 
nonessential amino acids, 10% FCS and antibiotics (for KLN205),  and in 
DME with 10% FCS and antibiotics (for LL/2 and NIH 3T3), respectively. 
The KM201, KM81, and IRAWB14 mAbs, recognizing epitopos on murine 
CD44 (27, 31), were used in purified form. 
Isolation of  Poly A +  RNA 
Poly  A  + RNA was isolated as described (1). Briefly, cultured cells were 
harvested, washed  in HBSS and lysed with lysis buffer (200 mM NaC1, 
200 mM Tris-HC1, pH 7.5, 1.5 mM MgCI2, 2% SDS and 0.2 mg/ml Pro- 
teinase K).  Oligo(dT)  cellulose (Collaborative Research,  Bedford,  MA) 
was  hydrated  in elution buffer (10 mM Tris-HC1,  pH 7.5),  followed by 
equilibration in binding buffer (500 mM NaCI,  t0 mM Tris-HC1, pH 7.5). 
The lysate and otigo(dT)  cellulose were mixed and incubated for 30 rain 
at room temperature with agitation.  The  oligo(dT)  cellulose  was  then 
washed with binding buffer and packed onto a Poly Prep Chromatography 
Column (Bio-pad Laboratories, Richmond, CA). The poly A + RNA was 
eluted with ehition buffer. 
Polymerase Chain Reaction 
One microgram poly A + RNA was reverse transcribed with 14 U AMV re- 
verse transcriptase (US Biochemic~ Corp., Cleveland, OH) in a 20-/~1  reac- 
tion primed with 0.7 t~g of oligo (dT)t2-1s (10). The reaction was assem- 
bled by  mixing poly  A + RNA,  oligo  (dT)12-1s and H20,  followed  by 
heating at 68"C for 4 rain and quenching on ice. Then 4 #1 of 5 x  first strand 
buffer (250 mM Tris-HC1, pH 8.3, 375 mM KCI,  15 mM MgCI2 and 50 
mM dithiothretol) (US Biochemical Corp.),  1 ~1 of 10 mM dNTP,  10 U 
RNasin (Promega Corp., Madison, WI) and 14 U AMV reverse transcrip- 
tase were added.  After 2 h at 39"C, the reaction was diluted with 1 ml TE 
(10 mM Tris-HCl, pH 7.5, 1 mM EDTA) and 10 td was used as template 
for the subsequent polymerase chain reaction (PCR). 
Two oligonucleotides  were synthesized for PeR priming. The upstream 
primer  OM-6AR,  5'-GGGAATTCG-CCA~GTTT'IV,-GTGG-Y 
corresponds to a 21-bp stretch overlapping the initiation codon ATG in the 
murine CIM4 eDNA clone MHR6 (45), whereas the downstream primer 
OM-2AR,  5'-GGGAATTCAATGC~GTAGC,-GCACTACA-3' is  comple- 
mentary to a 19 bp fragment around the stop codon TAG in the same done 
(45). Both oligonucleotides  had an EcoRI site added to the 5' end for use 
in cloning. 
The PCR cocktail was assembled in a  100 #1 reaction by mixing 10/~1 
template, 10/~1 of 10 x  PCR buffer (Promega  Corp.),  16/~1 of 1.25 mM 
dNTP, 0.2 nmol each of OM-tAR and OM-2AR, and 5 U Thermus aquati- 
cus (Taq) DNA polymerase (Promeba Corp.). After 40 cycles at 94"C for 
40 s, 55~  for 2 rain and 72"C for 2.5 rain, 5/zl of the reaction products 
were analyzed on a  1.2% agarose  gel and the remainder purified  using 
Geneclean (Bio 101 Inc., La Jolla, CA). 
Construction of  Mutant CD44ANC 
A  CIM4  mutant,  CIM4ANC,  lacking  the region between Vail61  and 
Arg244 (45) was made by loop out mntabanesis  involving a two-round PCR. 
An oligonucleotide  Blp124 complementary to sequences before Vall61 and 
after Arg244, 5'-C~TCTGAGGTCTCCTATCG'I~ATCTATAA'II3T- 
TTG-3', was  synthesized.  The first  round was primed by OM-tAR and 
Blp124 using the eDNA done MHR6 as the template,  resulting in a frag- 
ment containing all sequence up to that coding for Vail61 and a stretch en- 
coding Arg244 to Pro249. The product was purified, denatured by heating, 
and used as the upstream primer together with the downstream primer OM- 
2AR in a second round PCR with the same template,  which created mutant 
CIM4ANC.  The final product was sequenced  to confirm that the correct 
mutated sequenced had been obtained. 
cDNA Cloning and Sequencing 
The purified  PCR products were digested with EcoRI and subeloned into 
plasmid pBS(+) (Stratagone  Corp.,  La Jolla,  CA).  The nucleotide se- 
quences of the inserts were determined using the dideoxy chain termination 
method with Sequenase  (US Biochemical  Corp.)  from double-stranded 
templates.  Sequence  analysis  software  was from the Genetics Computer 
Group of the University  of Wisconsin. 
Construction of  Plasmids  for Expression 
The eDNA inserts were subcloned via blunt-end libation into a HindIH site 
of the expression vector pRe/RSV (Invitrogon,  San Diego, CA) which has 
an LTR promoter from Rous sarcoma virus, a polyadenylation  signal from 
the bovine growth  hormone and a  nee gane for selection in G418 sup- 
plemented media. 
Transfection by Electroporation 
Cells were  Wansfected by electroporation as described previously  (16). 
Briefly, AKR1 cells were suspended at 1.0 x  107/rnl in ice-cold PBS (Mg  2+ 
and Ca  2+ free).  0.5 ml of the cell suspension was transferred into a pre- 
cooled electroporation cuvette and 100 ~g of purified plasmid DNA was 
added.  The  cuvetm  was  then  pulsed  using  the  Gene Pulser  apparatus  (Bio- 
Pad Laboratories)  with  550  V and  25 ~F of  capacitance.  G418 was  added 
at  I  mg/ml  after  48  h  of  growth  and  drug-resistant  colonies  appeared  within 
2 to 3wk. The transfectants  were analyzed  by KM81 staining  and  bright 
populations were  sorted on  a  FACStarPIus  (Becton-Dickinson Im- 
munocytometry Systems, San Jose, CA). In contrast to the experience of 
another group who used fibroblasts  (40),  none of our AKR1 transfectants 
displayed any marked tendency for spontaneous aggregation. 
Northern and Southern Blotting 
Northern blotting was performed as described (32).  After electrophoresis 
on a 1.2% agarose gel, the PCR products were Southern blotted with vari- 
ous probes using procedures previously  descried (38).  The M4EX probe 
was created by PCR amplification  using primers of M4UP,  5~  - 
ACTCCACGGGTT-3',  and IDON,  5'-CGTTGGAG'IV.AGTAGC-3', from 
domain A and D, respectively (Fig. 3 a), whereas probe M4AB is the PCR 
product of domain A and B using M4UP and M3DON (5'-GCTTTCTGT- 
TTGATGACCTTG-3'). 
Cell Adhesion Assays 
Cell adhesion to HA immobilized on stromal cell layers was assayed as de- 
scribed (31). Briefly, 2  ￿  106 cells were washed,  suspended  in complete 
medium and incubated with 10 #Ci SlCr at 37~  for 1 h. The labeled cells 
were washed and added to 24-well plates (Coming Cell Well, Coming, NY) 
coated with a layer of the stroma cell line BMS-2 plated 24 h before the 
assay. Plates were incubated  with labeled cells for 2 h at 4"C. Unbound cells 
were removed by three cycles of washing in complete medium with vigorous 
agitation on a  minishaker (Dynatec  Laboratories Inc.,  Chantilly,  VA). 
Bound cells were lysed with 0.1 N NaOH/1% NP-40 and the SlCr counted 
with a gamma counter (Beckman Instruments Inc., Fullerton, CA). Percen- 
tages of  bound cells were calculated as previously described (31). The adhe- 
sion of transfected lymphoma cells to BMS2 stromal ceils is almost totally 
dependent on CIM4 and HA (27). This was confirmed in these studies by 
use of HA and KM201 monoclonal antibody treatment (27). 
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Fluorescein-conjugated  HA was prepared and used for soluble ligand bind- 
ing experiments as described (27) except that cells were tested in serum free 
medium. The degree of ligand binding was determined by flow cytometry 
with a FACScan (Becton Dickinson Immunocytometry Systems). Numbers 
of molecules  of bound fluorescein were determined by comparison of me- 
dian channel numbers with values obtained with Immunobright bead stan- 
dards (Coulter Corp., Hialeah, FL). The density of CIM4 on transfected 
cells was similarly determined by flow cytometry after immunofluorescent 
staining with the KM 81 monoclonal antibody. 
Cell Surface Biotinylation  and Immunoprecipitation 
Cells were surface labeled as described (32) and lysed with lysis buffer (50 
mM Tris-HC1, pH 7.5, 150 mM NaC1, 1% Triton X-100, 50 mM iodoaceta- 
mide, 0.1% NAN3, 1 mM phenylmethylsulfonyl  fluoride,  1 raM EDTA,  10 
~g/rnl of soybean trypsin inhibitor, 1 t~g/ml of leupeptin and 1 trypsin inhib- 
itor unit/rnl of aprotinin). The lysates were precleared with  100  ~tl of 
Afligel-10 (Bio-Rad Laboratories) conjugated  with rat serum, followed by 
immunoprecipitation  with 25/~1 of Atfigel-10 conjugated with either KM201 
anti-CIM4 antibody (2 mg/rnl) or rat IgG as a negative control. After rotat- 
ing 1 h at 4"C, the beads were washed twice with 50 mM Tris-HC1, pH 
83, 0.6 M NaCI,  0.2%  Triton X-100 and 0.1% NaNs, and once with 10 
rnM Tris-HCl, pH 7.5, 0.15 M NaC1 and 0.1% NaNs. Bound proteins were 
eluted by boiling 5 rain in reducing sample buffer and run on a 7.5% SDS- 
PAGE gel, followed by transfer to a trans Blot membrane (Bio-Rad Labora- 
tories). The membrane was blocked with 0.5% gelatin, 0.05% Tween-20 
and 0.05 % thimerosal in PBS for 1 h at room temperature, washed with 0.1% 
Tween-20 in PBS and incubated for 1 h with avidin HRP (Bio-Rad Labora- 
tories) diluted 1:3,000 with 0.5%  BSA and 0.05% Tween-20  in PBS. Bi- 
otinylated proteins on the membrane were visualized using the ECL West- 
ern blotting detection system (Amersham International, Arlington Heights, 
IL). Biotinylated  molecular weight markers were used as standards. 
Western Blotting 
CD44 proteins were enriched by immunoprecipitating the unlabeled lysate 
with KM201 conjugated  Afligel-10. The eluate was electrophoresed  on a 
7.5%  SDS-PAGE gel, transferred onto a trans Blot membrane which was 
then blocked as described above. The membrane was first incubated for 1 h 
with 10 ~tg/ml KM201 in 1% BSA, 0.05% Tween-20 and 0.05% thimerosal, 
washed  with 0.1% Tween-20  in PBS,  and then incubated with 1:10,000 
diluted HRP conjugated goat anti-rat IgG (Zymed Laboratories, Inc., San 
Francisco, CA).  The protein bands were detected  using the ECL system 
(Amersham Corp.).  Prestained molecular weight  markers were  used as 
standards. 
Results 
HA Binding Occurs in the Absence of the Membrane 
Proximal Domain 
Recent reports have described various molecular isoforms of 
CD44 in humans and rats (3, 8, 14, 17, 42). These differ from 
the isoform expressed by most hemopoietic cells in having 
additional sequences inserted in the membrane proximal do- 
main, which is the least well conserved part of the molecule. 
We investigated the importance of this region of the hemo- 
poietic form of  CD44 by mutagenesis and transfection experi- 
ments  (Materials and Methods).  A  construct producing a 
molecule which lacks 83 amino acids of this domain was 
transfected into AKR1 T lymphoma cells (AKR1.CIM4~NC). 
The sizes of the transcript and expressed protein were as pre- 
dicted (1.7 kb and 58 kD, data not shown and Fig. 6 below). 
The epitope on CD44  which is recognized by the mono- 
clonal antibody IRAWB14,  as well as others defined by a 
panel of 22 antibodies, were all present in the mutated mole- 
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Figure I. The membrane proximal domain of CIM4 is not essential 
for recognition of soluble hyaluronate. Surface densities of CIM4 
(left) on an HA binding B lineage hybridoma (BM2) were deter- 
mined by flow cytometry and compared with lymphoma cells trans- 
fected with either wild-type CD44 (CD44WT) or a mutant lacking 
the membrane proximal domain (CIM4ANC). Shaded histograms 
depict unstained cell profiles and open histograms depict staining 
with FYIC-labeled anti-CD44  antibody KM81. Flow cytometry 
results shown on the right depict binding of soluble fluorescein- 
labeled HA when tested alone (shaded), or when the enhancing 
IRAWB14 monoclonal antibody was added at the same time as the 
ligand (open). 
cule (data not shown). We then evaluated the ability of the 
transfected lymphoma cells to recognize soluble fluorescein 
labeled HA (Fig.  1). The density of CD44 on this transfec- 
tant was ,v36 % of  that on our previously described wild-type 
CD44  transfectant (AKR1.CD44WT).  Nonetheless,  there 
was constitutive recognition of  the soluble HA Iigand, which 
was markedly augmented in the presence of the inducing 
IRAWB14  monoclonal antibody,  In contrast to the AKR1 
lymphoma transfectant, maximum HA binding was constitu- 
tive with the BM2 B cell hybridoma and was usually unaf- 
fected by pretreatment with the IRAWB14  antibody.  Note 
that BM2 cells appear to express the same "hemopoietic"  iso- 
form as other blood cells (see below). We conclude that the 
binding site for HA is in the amino terminal two thirds of 
CD44 and that the membrane proximal domain is not essen- 
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Figure 2. PCR amplification of CIM4 from various cell lines, nor- 
real tissues and transfectants. Total or poly A selected RNA from 
various sources were reverse transcribed and PCR amplified using 
oligonucleotides OM-6AR and OM-2AR as detailed in Materials 
and Methods.  The top illustrates  the  ethidium  bromide  stained 
products separated on a 1.2 % agarose gel and visualized by UV illu- 
mination.  The  same  PCR  products  were  transblotted  onto  a 
nitrocellulose membrane and hybridized with eDNA probe M4EX 
as described  in Materials  and Methods.  The resulting autoradio- 
gram is shown in the bottom. 
tial for this function.  Furthermore, the shortened molecule 
is fully responsive to the effects of the IRAWB14 antibody. 
Molecular lsoforms of Murine CD44 
Polymerase chain reactions were used to screen for murine 
cell lines which might synthesize high molecular weight iso- 
forms of CD44. A squamous cell carcinoma (KLN205) was 
found to contain transcripts other than the expected 1.1  kb 
species when primers were used which span the coding se- 
quence for the hemopoietic form of murine CD44 (Fig. 2). 
With this cell line, at least four discrete bands, correspond- 
ing to transcripts of 1.4,  1.5, 1.8, and 2.0 kb were resolved. 
Each band was purified by gel electrophoresis, digested with 
EcoRI, ligated into the pBS(+) plasmid and their nucleotide 
sequences determined. At least two independent clones were 
obtained from each, representing identical sequences. Each 
of these transcripts,  which  we designate M1-M4,  encode 
CD44 isoforms which differ from the hemopoietic isoform 
by insertions after Thr 202 in the membrane proximal do- 
main,  extending  the  molecule by 99,  134,  216,  and  293 
amino  acids,  respectively  (Fig.  3).  The  longest  isoform 
(M4), has an additional six potential N-linked and 14 poten- 
b 
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Figure 3. Complete eDNA sequences are shown for four new mu- 
rine CD44 isoforms (a). The site of insertions in the previously de- 
scribed"hemopoietic" isoform is indicated relative to the prote~gly- 
caiflike "core" and transmembrane (TM) domains. Solid and dotted 
lines indicate potential N- and O-linked glycosylation sites, respec- 
tively. The blocks and letters on the left designate domains which 
are utilized in the various isoforms and the combinations found are 
depicted in b. These sequence data are available from EMBL/Gen- 
Bank/DDBJ under accession numbers X66081-X66084. 
tial O-linked glycosylation sites￿9 The only homology found 
for these new sequences by computer search was with re- 
cently described human and rat CIM4 isoforms (17). Two of 
the  four murine  isoforms  (M1  and  M2)  had  exact homo- 
logues in other species and two (M3 and M4) represented 
unique combinations of sequences previously found in one 
rat isoform (see Discussion). With the exception of an NH:- 
terminal stretch of 42 residues and two small gaps required 
for alignment of the routine and rat sequences, there was 
88% identity between these two species (Fig. 4). 
PCR amplification products obtained with RNA from a 
variety of cell  lines  and  tissues  were further assessed by 
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Figure 4. Protein sequence comparison of inserted residues in mouse and rat CD44 isoforms. The unique sequence from the new murine 
CD44M4 isoform (top) is compared with the longest CD44 isoform which was recently discovered in rats (17). Identical residues are aligned 
with vertical bars, whereas colons and dots between lines indicate conserved and less conserved replacements, respectively. Blanks represent 
nonconserved changes and gaps within the sequence were introduced for best alignment. 
Southern blotting (Fig. 2) with a probe (M4EX) correspond- 
ing to the longest (M4)  inserted  sequence  (Fig.  3  a).  With 
this  approach,  lung  was the  only  normal  tissue  examined 
which clearly had an alternative form of CD44,  This tran- 
script corresponded  in size to the M2 isoform (1.5 kb) and 
did not hybridize with probe M4AB specific for M3 and M4 
isoforms  (data not  shown).  Furthermore,  in Northern  blot 
analysis using probe M4EX,  an additional transcript (,~5.3 
kb in size) was only found in lung samples (Fig.  5 b below, 
and data not shown).  All other samples had the three bands 
("-,4.6, 3.3, and 1.8 kb) which have been repeatedly found by 
Northern  blotting with murine hemopoietic cell RNA  (27) 
and  which  presumably  differ with  respect to untranslated 
nucleotides. 
Expression and Functional Assessment of New 
CD44 lsoforms 
Each of the four new transcription products was ligated into 
an  expression  vector and  transfected  into the AKR1  lym- 
phoma cell line. The resulting transcripts were evaluated by 
Figure 5. Northern blot analysis. RNA samples from the indicated 
cell lines and tissues were fractionated on a 1% agarose gel, trans- 
blotted onto a nitrocellulose membrane, and (A) hybridized with 
cDNA representing the full length "hemopoietic" CD44  isoforrn 
(CD44WT). The same blot was reprobed (B) with M4EX described 
in Materials and Methods.  This probe corresponds to the unique 
inserted sequence found in our longest murine isoform (M4). The 
blot was deliberately overexposed to demonstrate the absence of 
variant CD44 isoforms in BM2 cells. 
Figure 6. Expression of  CD44 protein isoforms as revealed by West- 
ern blot (A) or cell surface labeling and immunopreeipitation (B). 
Cells were lysed and immunoprecipitated with either anti-CD44 
mAb KM201 (IgG1) or anti-VCAM-1 mAb M/K-1 (IgG1). The pre- 
cipitates were eluted by boiling 5 min in nonreducing sample buffer, 
run  on a  SDS-PAGE gel  and  transblotted  onto a  nitrocellulose 
membrane. CD44 proteins were then detected by mAb KM20t and 
HRP-conjugated goat anti-rat Ig using the ECL system (,4). The 
mobilities of prestained molecular weight markers are indicated. 
cells were also surface biotinylated,  solubilized and immunopre- 
cipitated with mAb KM201. Immunoprecipitates were separated on 
a SDS-PAGE gel under reducing conditions, transferred onto a ni- 
trocellulose membrane and detected with HRP-conjugated avidin 
using the ECL system (B). The mobilities of  biotinylated molecular 
weight markers are indicated. 
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Figure 7.  New  murine CD44 isoforms  can mediate adhesion of 
transfected cells to the BMS2 stromal cell clone. The levels of ex- 
pression of CD44 in each of the transfectants was determined sep- 
arately by flow cytometry as described in Materials and Methods. 
In three assays, these averaged 41% (M/), 32% (M2), 11% (M3), 
28% (M4), 36% (~uVC)and 238% (BM2)of the wild-type transfec- 
rant. No attempt was made to normalize the findings with respect 
to these differences.  The extent of  constitutive  adherence of  radiola- 
beled transfectants to monolayers of BMS2 cells is shown (open 
bars). The dependence of this adhesion on CD44 was determined 
by inclusion of the blocking KM 201 antibody (closed bars). Bind- 
ing was also assessed in the presence of the enhancing IRAWB14 
monoclonal antibody (cross-hatched bars). The results are typical 
of three similar experiments. 
Northern blotting and prominent transcripts of the expected 
sizes (wild type =  1.9; M1 =  2.2 kb; M2 =  2.4 kb; M3 = 
2.6 kb; M4 =  2.8 kb) were found (data not shown). Protein 
products made by hemopoietic and carcinoma cells were 
compared by Western blotting (Fig. 6 A), revealing a broad 
range of CIM4 species in the latter cell type. Transfectants 
were surface labeled and immunoprecipitateA to determine 
sizes of the expressed proteins. As in our previous study, the 
wild-type, hemopoietic isoform was ,080 kD when expressed 
in  the  transfected  lymphoma  cells  (27).  The  mutated 
AKR1.CD44ANC construct produced an '-58-kD protein. 
Single protein species were obtained  with each of  the new iso- 
forms corresponding to 110 kD (M1), 120 kD (M2), 140 kD 
(M3), and 160 kD (M4) under reducing conditions. Sizes 
predicted from the cDNA  sequences of these molecules, 
without regard to glycosylation  would be 48.1, 51.7, 60.7, and 
69.5 kD, respectively. The ratio of predicted to actual sizes 
was constant (0.43) among all of  the transfectants, indicating 
that posttranslational modifications were proportional to the 
lengths of the polypeptides. 
All transfectants displayed measurable adhesion to an ad- 
herent stromal cell line, which was previously shown to bear 
HA (31) (Fig. 7).  The CD44 dependence of this adhesion 
was confirmed by addition of the blocking KM 201 antibody. 
Pretreatment of the adherent layer with HA also reduced the 
binding by an average of 85 % (data not shown). Adhesion 
was increased, and in some cases, dramatically, when the en- 
hancing IRAWB14 antibody was present. Binding of the new 
isoform  transfectants  was  less  than  with  the  wild-type 
hemopoietic isoform transfectant or BM2 hybridoma cells, 
which expressed substantially higher densities of CD44. For 
example, the M3 transfected cells had only 11%  as much 
CD44 as wild-type transfected cells and displayed corre- 
sponding low constitutive binding to BMS2 monolayers. In 
an experiment done with a higher expressing subclone of 
M4, adhesion was nearly equivalent  to that obtained with the 
wild-type CI)44 transfectant (data not shown). In contrast, 
cells beating the mutated CD44ANC molecule had surface 
densities comparable to the M2 and M4 transfectants, but an 
average of only 10% binding was observed in three indepen- 
dent experiments. In the same experiments, binding with 
M2, M4, and wild-type CD44 transfectants were 49, 35, and 
77%,  respectively.  This  inefficient binding  was  also  in- 
creased when the IRAWB14 antibody was present. It should 
be noted that these assays were performed at 4~  to avoid 
potential activation of  the cells by either ligand or antibodies. 
Studies done with LFA-3 demonstrated that differences relat- 
ing to the overall length of that molecule are particularly 
noticeable at that temperature (5). 
Recognition of soluble HA was assessed by flow cytome- 
try, where densities of surface CIM4 on each transfectant 
could be compared with their ligand binding abilities (Fig. 
8). Constitutive HA binding was extremely low with some 
of these cell lines, but in every case, this increased when the 
IRAWB14  antibody  was  present.  In  that  situation,  the 
amount of HA bound tended to be proportional to the density 
of CIM4 on the cell surface. No obvious pattern was ob- 
served where particular isoform sequences correlated with 
high or low HA binding. 
These experiments demonstrate that all five known murine 
CD44 isoforms are able to confer HA recognition ability on 
transfected T lymphoma cells. The constitutive avidity for 
soluble ligand may be very low, but was sufficient  to mediate 
adhesion to cells whose surfaces are coated with HA. All 
forms of CIM4 in this T lymphoma model were responsive 
to the enhancing IRAWB14 monoclonal antibody, which dra- 
matically increased binding to both soluble and cell immobi- 
lized ligand. This contrasts to the situation with B lineage hy- 
bridoma cells, which displayed very high HA recognition 
that was not consistently affected by IRAWB14 (Fig. 1). The 
enhancing antibody may mimic the interaction of some un- 
known ligand with CD44, when it is expressed on particular 
cells. 
Discussion 
These experiments address the importance of particular ex- 
tracellular domains of CIM4 for recognition of soluble or 
immobilized HA.  We found that the amino terminal two 
thirds of the extracellular portion of the molecule bears epi- 
topes recognized by a number of antibodies to murine CD44 
and can mediate recognition of the ligand HA. Four new rou- 
tine isoforms were characterized and circumstances found in 
which all mediated adhesion when expressed in transfected 
lymphoma cells. These findings increase our understanding 
of molecular polymorphisms of  CIM4 and indicate that vari- 
ations in the membrane proximal region do not per se pre- 
vent HA recognition. They also extend recent observations 
of variable isoforms of rat and human CD44  to murine 
CD44. 
Our results show that the amino terminal region of CIM4, 
which bears homology to other HA binding proteins (41, 
45), is clearly sufficient for HA recognition when expressed 
on T lymphoma cells. However, a number of recent findings 
have focused attention on the less well conserved membrane 
proximal portion of this molecule. First, this domain of hu- 
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Figure 8. The density of  CD44 on transfected  ceils influences  bind- 
ing of soluble ligand. Flow cytometry was used to determine the 
density of CIM4 (numbers of FITC molecules bound by treatment 
with labeled anti-CIM4 antibody) and binding of HA (number of 
FITC molecules bound after brief exposure to labeled HA). Closed 
symbols represent constitutive  ligand binding ability and open sym- 
bols depict HA binding when the enhancing IRAWB14 antibody 
was present. The data are from two independent  experiments where 
untransfected AKR1 lymphoma cells (,,<>), wild-type transfec- 
tants (v,v),  and cells expressing the CD44ANC mutant (A,/,) 
were compared to cells transfected with the new murine CD44 iso- 
forms M1, M2, M3, M4 (m,c2). 
man CD44 bears the Hermes 3 epitope, which is thought to 
be functionally associated with lymphocyte homing and to 
interact with another ligand (13). This segment also contains 
several chondroitin sulfate addition sites and, when these are 
utilized, CD44 becomes capable of recognizing collagen and 
fibronectin, as additional ligands (9, 23). Furthermore, this 
high molecular weight form of chondroitin sulfated CD44 
may confer a  more aggressive phenotype on tumor cells 
which express it (9). Additional molecular heterogeneity of 
CD44 has been found to result from insertions of sequences 
of variable length in the membrane proximal domain (3, 6, 
8,  12,  14,  17, 20,  39, 42). 
A  wide variety of cell types are now known to express 
some form of CD44. These include most blood cells, fibro- 
blasts, bone marrow stromal cells and epithelial cells (15). In 
some cases, these have been shown to differ with respect to 
polypeptide length, as well as the degree and nature of post- 
synthetic modification by glycosylation (3).  There is also 
reason to suspect that the same form of CD44 may function 
differently in different cell types. For example, HA binding 
is constitutively maximal in the BM2 hybridoma line and 
unaffected by the IRAWB14 antibody (Fig.  1). This may be 
comparable to B cells from mice undergoing graft versus 
host disease or exposed to interleukin 5, which had high in- 
trinsic avidity for HA (33,  34).  Similar sized CD44 mole- 
cules on T lymphocytes and lymphoma lines display moder- 
ate avidity for this ligand and HA binding is dramatically 
enhanced by IRAWB14. Still another pattern is found on rest- 
ing splenic B lymphocytes and bone marrow cells, which 
bear the hemopoietic isoform of CD44, but do not adhere 
to HA regardless of whether IRAWB14 is present (27 and J. 
Lesley, unpublished observations). In contrast to our results 
with the murine M2 form of CD44 expressed in lymphoma 
cells, the homologous epithelial form of human CD44 failed 
to bind HA when expressed in a pre-B lymphoma (42, 43). 
These cell type specific differences might be attributable to 
associations of CD44 with other proteins or to differences 
in posttranslational modification of the CD44 molecule it- 
self. We found that the cytoplasmic domain of the molecule 
is important for constitutive high recognition of HA (27). 
Others recently reported cell type specific differences in as- 
sociation with cytoskeletal elements, which may be related 
to the phosphorylation of cytoplasmic serine residues (2, 4, 
21, 22, 26). This is an important area for further investiga- 
tion and one that might be approached by transfection of  mul- 
tiple cell types with the same constructs. 
The mechanism through which the IRAWB14 antibody 
enhances CD44 mediated binding of  HA remains unclear. En- 
hancement occurs within seconds to minutes of adding anti- 
body and occurs at 4~  The antibody can enhance HA bind- 
ing by CD44 molecules which lack a cytoplasmic domain 
and on cells which have been fixed  by paraformaldehyde  treat- 
ment (reference 27, and our unpublished observations). By 
analogy to antibodies which are known to increase ligand 
binding by an integrin (35),  IRAWB14 may cause a confor- 
mational change in CD44.  Other possibilities include anti- 
body influences on association of CD44 with other proteins 
or on focal clustering on the cell surface. The epitope recog- 
nized by IRAWB14 was present on the AKR1.CD44ANC mu- 
tant and recognition of  soluble HA was as markedly increased 
as it was with the new murine isoforms we characterized. We 
assume that shortening the molecule by mutation resulted in 
the relatively inefficient binding of transfected cells to HA 
coated stromal cells (Fig. 7). A minimal overall length may 
be required for interaction with immobilized ligand. Artificial 
lengthening of another adhesion molecule was reported to 
substantially increase function, particularly at cold tempera- 
ture (5).  Even this parameter was dramatically increased in 
our shortened CD44 transfectant by the enhancing IRAWB14 
antibody. 
At least 15 CD44 isoforms, which differ with respect to 
inserted or deleted sequences have now been found in tran- 
scripts expressed by rat, human, and murine cells. Included 
in that number are two unique murine isoforms (M3 and M4) 
characterized here. These represent "domains IV and V" or 
"domains II, III, IV, and V; respectively, as designated in a 
recent characterization of human and rat CD44  isoforms 
(17).  Our  M1  isoform is comparable to a  human species 
designated "variant C" in a recent publication (20) and our 
M2 isoform is equivalent to the "epithelial" variant described 
by several  laboratories  (3,  17,  42).  A  short stretch of 31 
amino acids  is  deleted  in  certain  neuroblastomas which 
represents  the  NH:-terminal  boundary  of the  insertions 
(39).  This incredible molecular diversity most likely results 
from alternative exon splicing (6), as is thought to be the case 
for generation of  N-CAM isoforms (7). Inspection of  all pub- 
lished eDNA sequences indicates that heterogeneity involv- 
ing  just the membrane proximal region of  the molecule could 
result from differential utilization of at least nine exons. 
Overall, the membrane proximal region of CD44 is the 
least well conserved portion of the molecule and is only 50% 
identical between humans and mice. However, there is con- 
siderable homology between the insertions that occur in this 
region with the various isoforms. For example, murine and 
rat insertions are 88 % identical (Fig. 4). It is also noteworthy 
He et at. Murine  CD44 Isoforms  1717 that Ala and Thr (position 201/202 in the mouse) have almost 
universally been found at this boundary in murine, rat and 
human CD44 sequences (3,  14,  17, 20). The longest inser- 
tion in the murine sequence (M4) nearly doubles the extra- 
cellular length of the molecule and introduces an additional 
20 potential glycosylation sites.  Although our experiments 
do not indicate that this region controls HA recognition, it 
may well be responsible for mediating other isotype specific 
CD44  functions. We isolated multiple isoforms of murine 
CD44 from a carcinoma line which was originally character- 
ized for high metastasis to the lung and it is interesting that 
novel rat CD44 isoforms were discovered in a tumor which 
had the same property (14, 25). It remains to be determined 
if HA and/or some other ligand are responsible for selective 
migration of certain CD44 beating tumors to that organ. 
It has also been noted that the human insertions include 
a potential cleavage site (Arg Arg) for trypsin like proteases 
(8). The same dipeptide is present at the corresponding posi- 
tion of insertions in rodent CD44 isoforms, as well as near 
the  transmembrane  segment  of the hemopoietic  isoform. 
This would presumably increase the possibility of generating 
soluble CD44 by means of enzymatic cleavage and we have 
detected soluble CD44 in murine serum,  as well as in the 
supernates of transfected cells (S. Katol and E  W. Kincade, 
unpublished observations). 
The hemopoietic isoform appears to be the most common 
and abundant species of CD44 in the murine tissues we ex- 
amined. Lung was the only untransformed source expressing 
any other isoform in our study and this species probably cor- 
responds to the M2 isoform which we isolated from carci- 
noma ceils. However, we consider it likely that multiple iso- 
forms  of CD44  are  synthesized at  some  level  by  normal 
murine tissues.  For example,  a tailless  isoform was origi- 
nally cloned from human cells and subsequently shown to 
represent a very low abundance transcription product in sev- 
eral  species  (12).  The  sequence  information we  obtained 
may now make it possible to prepare isoform specific mono- 
clonal antibodies and develop other approaches to under- 
standing the distribution and functions of these molecules. 
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